NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration.
As titanium dioxide nanoparticles (TiO(2) NPs) are widely used commercially, their potential toxicity on human health has attracted particular attention. In the present study, the oral toxicological effects of TiO(2) NPs (dosed at 0.16, 0.4 and 1 g kg( - 1), respectively) were investigated using conventional approaches and metabonomic analysis in Wistar rats. Serum chemistry, hematology and histopathology examinations were performed. The urine and serum were investigated by (1)H nuclear magnetic resonance (NMR) using principal components and partial least squares discriminant analysis. The metabolic signature of urinalysis in TiO(2) NP-treated rats showed increases in the levels of taurine, citrate, hippurate, histidine, trimethylamine-N-oxide (TMAO), citrulline, alpha-ketoglutarate, phenylacetylglycine (PAG) and acetate; moreover, decreases in the levels of lactate, betaine, methionine, threonine, pyruvate, 3-D-hydroxybutyrate (3-D-HB), choline and leucine were observed. The metabonomics analysis of serum showed increases in TMAO, choline, creatine, phosphocholine and 3-D-HB as well as decreases in glutamine, pyruvate, glutamate, acetoacetate, glutathione and methionine after TiO(2) NP treatment. Aspartate aminotransferase (AST), creatine kinase (CK) and lactate dehydrogenase (LDH) were elevated and mitochondrial swelling in heart tissue was observed in TiO(2) NP-treated rats. These findings indicate that disturbances in energy and amino acid metabolism and the gut microflora environment may be attributable to the slight injury to the liver and heart caused by TiO(2) NPs. Moreover, the NMR-based metabolomic approach is a reliable and sensitive method to study the biochemical effects of nanomaterials.
Bu
Qian
Q
State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Yan
Guangyan
G
Deng
Pengchi
P
Peng
Feng
F
Lin
Hongjun
H
Xu
Youzhi
Y
Cao
Zhixing
Z
Zhou
Tian
T
Xue
Aiqin
A
Wang
Yanli
Y
Cen
Xiaobo
X
Zhao
Ying-Lan
YL
D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D005260:Female; D006321:Heart / Q000187:drug effects; D006651:Histocytochemistry; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D055442:Metabolome / Q000187:drug effects*; D055432:Metabolomics / Q000379:methods*; D053768:Metal Nanoparticles / Q000737:chemistry / Q000633:toxicity*; D009206:Myocardium / Q000473:pathology; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods*; D025341:Principal Component Analysis; D051381:Rats; D017208:Rats, Wistar; D044967:Serum / Q000737:chemistry; D014025:Titanium / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity*; D014556:Urine / Q000737:chemistry
C009495:titanium dioxide; D014025:Titanium